Company / Operating Cash Flow
Mineralys Therapeutics, Inc. Operating Cash Flow History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$166.3M
FY2024
5-year range
-$166.3M / -$29.2M
FY2022-FY2024
Trend
-104.9%
vs FY2023
Sector context
#154 of 216
Health Care
What the data says
At -$166M, Mineralys Therapeutics, Inc.'s operating cash flow ranks #154 of 216 in the Health Care sector. Declined from -$29M to -$166M over the past 2 years.
Based on SEC 10-K filings.
-$166M in FY2024.
Declined from -$29M to -$166M over the past 2 years.
Health Care sector context is included.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#154 of 216 in Health CareTop 71% of 216This company -$166.3M Sector average $658.7M
▼
-125.2% below sector average
Key checks
Key Insights
- In FY2024, operating cash flow decreased 104.9% year-over-year.
- Ranks #154 out of 216 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | -$166.3M | -104.9% |
| FY2023 | -$81.2M | -177.8% |
| FY2022 | -$29.2M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026